# Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male

> **NCT03583021** · NA · COMPLETED · sponsor: **Ajou University School of Medicine** · enrollment: 42 (actual)

## Conditions studied

- Gallbladder Diseases

## Interventions

- **DRUG:** Sugammadex Injectable Product
- **DRUG:** Neostigmine Injectable Product

## Key facts

- **NCT ID:** NCT03583021
- **Lead sponsor:** Ajou University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-25
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583021, "Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03583021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*